Vor Biopharma Inc.

NASDAQ:VOR

Biotechnology

Healthcare
$17.83 -2.26%

-$0.34 today

Market cap
$966.13M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$2,053.13
52W Low $4.28High $65.80

Volume 0.79M

Average 1.07M

VOR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Vor Biopharma Inc.NASDAQ: VOR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $219.59M (cash outflow) rose 575.9% year over year, behind the +644.6% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +96.2% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$67.36M (-90.3%) for the fiscal year ending Dec 2026, a slowdown from the +495.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$219.59M-112.7% QoQ
Last fiscal yearDec 2025
-$695.98M+495.3% YoY
LTMMar 2026
-$883.08M+644.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+575.9%-100.0%-675.9 pp
1 year+495.3%-90.3%-585.6 pp
3-year CAGR+96.2%-63.6%-159.8 pp
5-year CAGR-69.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(695.98M) USD
Year-over-year change
-495.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VOR compares with its peers on the latest reported figures

  • VOR's LTM Mar 2026 net income of $883.08M is the largest of the 10 companies compared; the peer median is $209.38M.
  • Its year-over-year change of +644.6% is the highest of 10, against a peer median of -6.6%.
  • Over three fiscal years its annual growth of +96.2% compares with a peer median of -3.2%.
VOR Competitors Peer median
Net Income for VOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$883.08M +644.6%+96.2%—
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M -4.8%+3.1%757.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026$456.14M -6.6%-3.6%1812.1%
AUTLAutolus Therapeutics plcLTM Mar 2026$288.97M +21.3%+24.5%312.1%
SANASana Biotechnology, Inc.LTM Mar 2026$241.99M +16.0%-3.2%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$209.38M -18.9%+0.2%—
FATEFate Therapeutics, Inc.LTM Mar 2026$129.91M -26.1%-21.5%2056.8%
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M -56.6%-10.1%281.6%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$107.79M +391.1%-58.2%—
NKTXNkarta, Inc.LTM Mar 2026$99.93M -10.2%-2.9%—
Peer median (excluding VOR) $209.38M-6.6%-3.2%757.9%

Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Depreciation & Amortization1.43M2.53M3.49M3.53M2.89M
Deferred Income Tax00000
Stock-Based Compensation4.32M10.7M13.36M9.85M18.91M
Change in Working Capital(9.19M)(12.69M)650K5K10.21M
Accounts Receivables00000
Inventory00000
Accounts Payables405K02.85M2.24M0
Other Working Capital(9.59M)(12.69M)(2.2M)(2.24M)10.21M
Other Non-Cash Items3.19M6.42M67K3.87M521.26M
Operating Cash Flow(69.14M)(85.14M)(100.29M)(99.66M)(142.71M)
Capital Expenditures(3.89M)(8.46M)(1.07M)(229K)(941K)
Acquisitions (Net)00000
Purchases of Investments(87.76M)(123.19M)(74.92M)(9.91M)(53.66M)
Sales of Investments037.56M147M107M5M
Other Investing Activities0000799K
Investing Cash Flow(91.65M)(94.09M)71.01M96.86M(48.8M)
Debt Repayment00000
Common Stock Issued189.2M115.98M4.58M55.83M505.13M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.66M)1.17M(1.64M)(2.43M)(1.33M)
Financing Cash Flow232.91M117.14M2.94M53.39M503.81M
Effect of Forex Changes00000
Net Change in Cash72.12M(62.1M)(26.35M)50.59M312.29M
Free Cash Flow(73.04M)(93.61M)(101.36M)(99.89M)(143.65M)

Vor Biopharma Inc.

NASDAQ:VOR

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.